BeyondSpring Pharmaceuticals
2 known investors
BeyondSpring is a clinical-stage pharmaceutical company developing Plinabulin, a cancer drug candidate studied for reducing chemotherapy-induced neutropenia and, in combination with radiation and PD-1/PD-L1 inhibitors, treating patients who failed prior immune checkpoint therapy. Its work spans multiple cancer indications across phase 1 to phase 3 clinical trials.